100% protection against severe disease Final analysis in U.K. trial confirms 96% efficacy against original strain of COVID-19 Efficacy against variants confirmed in U.K. and South Africa GAITHERSBURG, Md., March 11, 2021 — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced final efficacy of 96.4% against mild, […]
